Focusing on "AI+Drug Delivery", DynaTech Pharmaceuticals Closes $100 Million Series C Funding Round

Founded in 2020, DynaTech Pharmaceuticals was co-founded by Hongmin Chen, a member of the U.S. Academy of Engineering, as well as Dr. Caida Lai and Dr. Wenshou Wang, top scientists at MIT. The company has become one of the world's leading drug delivery platforms by utilizing artificial intelligence to drive precision targeted drug delivery and drug discovery, and is committed to developing innovative nanomaterials and more effective therapeutics for patients. The funds from this round of financing will also be used to continue to promote the construction of the AI+ drug delivery platform and the development of the self-research pipeline, which will help DynaTech continue to innovate in the field of drug delivery.

AI + drug delivery to accelerate CGT and nucleic acid drug development

According to Nova One Advisor's latest forecast, the CGT and mRNA therapeutics market size is expected to soar to $156.2 billion by 2033[1],2 and this huge market potential has attracted the attention of many investors and companies. In the process of CGT and mRNA drug development, "drug delivery" technology is the "choke point" to ensure its smooth entry into the cell for expression, which involves key issues such as targeting tissues and organs, efficient intracellular delivery and endosomal escape. Figuratively speaking, the delivery process is like a rocket precisely sending a satellite into a specific orbit so that the satellite can operate normally.

As a leading company in the field of "AI+Drug Delivery", DynaTech has developed pioneering AI and computational simulation algorithms for ionizable lipid generation and design, and LNP nanomaterials design and simulation from scratch without open source datasets and delivery-related algorithms, combined with the world's leading high-throughput experimental and animal validation platforms. technology and animal validation platform, and established its own data and algorithmic barriers. At present, DynaTech has independently developed three major AI+ core technology platforms: AI-driven nucleic acid delivery system design platform (AiLNP), AI-driven mRNA sequence design platform (AiRNA), and AI-driven small molecule formulation design platform (AiTEM), and created an exclusive DynaTech's deep combination of wet and dry experiments technology route, thereby realizing efficient drug delivery and drug discovery.

Based on the AI drug delivery platform, combined with the rapidly developing large model and generative AI technology, Dosage Pharma has established the world's first METiSLipidLM lipid language model and PhatGPT lipid generation model, created a million lipid libraries, and successfully broken through the international patent barriers. At the same time, DynaTech combines innovative molecular simulation technology to simulate the microscopic processes of LNP in vivo and in vitro, and relies on the world's top experimental validation platform to empower the development of multi-organ targeted nanomaterials, realizing the successful landing of the application of AI+Nanomaterials.

In the field of liver targeting, PharmaTech has achieved the best-in-class in the world, with delivery efficiency exceeding that of industry giants by more than 20 times. In the field of lung targeting, Dyna-Tech has also achieved an order of magnitude improvement in efficacy against the top overseas pharmaceutical companies. In addition, DynaTech has also pioneered targeted delivery technologies for whole body muscle, brain, immune organs and tumors, successfully leading the world in overcoming the "choke point" problem of multi-organ and tissue targeting, and bringing opportunities for nucleic acid gene-based drugs in the fields of tumors, metabolic disorders, autoimmune disorders, and neurological aging disorders.

First Pipeline Advances to Clinical Phase III

Relying on its self-developed technology platform, DynaTech has built several R&D pipelines covering small molecule drugs and mRNA-based nucleic acid drugs, focusing on indications with high clinical demand in China and around the world, such as oncology, central nervous system disorders and liver diseases.

The fastest-progressing small molecule pipeline has successfully started Phase III clinical trials in June 2023, and the mRNA immunotherapy pipeline is expected to enter the clinic this year. It means that the company has completed the rapid transformation and upgrading of its technology platform to product platform, which validates the R&D capability of Agent Pharma's AI-driven drug delivery platform.

The Series C financing will further accelerate Dosage Pharma's R&D process and enhance the company's competitiveness in the field of AI drug development. Dosage Pharma will utilize the funds from this round of financing to continue to strengthen its team building and promote the development and clinical application of more innovative drugs.

Two-wheel drive of "independent research and development + co-development".

In addition to independent research and development, DynaTech also actively seeks external cooperation, and promotes the development of the enterprise with the dual-wheel drive mode of "independent research and development + co-development". At present, through co-development or technology platform external authorization, DynaTech has carried out in-depth cooperation with domestic and foreign top pharmaceutical companies, the technology platform of the research and development speed and success rate have been recognized by the industry. Through close cooperation, Dyna-Thai Pharma is expected to achieve technological breakthroughs and commercialization applications worldwide, contributing more to the progress of the pharmaceutical industry.

We are honored to receive this round of financing, which will provide a strong impetus for the further development of Agent Pharma in the field of AI drug discovery and development," said Dr. Lai Choy Tat, Co-Founder & CEO of Agent Pharma. We understand that the next 2-3 years will be a very critical period for the industry, with the development of nano-delivery materials accelerating globally and major pharmaceutical companies actively seeking long-term drug delivery partners. We are firmly committed to advancing 'AI+drug delivery' technology and aim to become the Space X of the pharmaceutical industry, designing world-class nano rockets and solving the industry's most challenging technical problems. At the same time, we look forward to working with the industry's best pharmaceutical companies to build China's nucleic acid drug ecosystem and bring more innovative drugs to the clinic."